

CORRECTED VERSION

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
27 July 2000 (27.07.2000)

PCT

(10) International Publication Number  
WO 00/43395 A1

- (51) International Patent Classification<sup>7</sup>: C07D 487/22. C09B 47/00. A61K 51/02
- (21) International Application Number: PCT/US00/02062
- (22) International Filing Date: 25 January 2000 (25.01.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/117,010 25 January 1999 (25.01.1999) US
- (71) Applicants: NATIONAL JEWISH MEDICAL AND RESEARCH CENTER [US/US]; 1400 Jackson Street, Denver, CO 80206 (US). AEOLUS PHARMACEUTICALS, INC. [US/US]; P.O. Box 14287, Research Triangle Park, NC 27709 (US). DUKE UNIVERSITY [US/US]; 230 North Building, Research Drive, Box 90083, Durham, NC 27708-0083 (US).
- (72) Inventors: CRAPO, James, D.; National Jewish Medical and Research Center, 1400 Jackson Street, Denver, CO 80206 (US). DAY, Brian, J.; National Jewish Medical and Research Center, 1400 Jackson Street, Denver, CO 80206 (US). TROVA, Michael, P.; Albany Molecular Research, Inc., 21 Corporate Circle, Albany, NY 12203 (US). GAUUAN, Polivini, Jolicia, F.; Albany Molecular Research, Inc., 21 Corporate Circle, Albany, NY 12203 (US). KITCHEN, Douglas, B.; Albany Molecular Research, Inc., 21 Corporate Circle, Albany, NY 12203 (US). FRIDOVICH, Irwin; 3517 Courtland Drive, Durham, NC 27707 (US). BATINIC-HABERLE, Ines; Apartment G2, 3031 Weymouth Street, Durham, NC 27707 (US).
- (74) Agent: WILSON, Mary, J.; Nixon & Vanderhye P.C., Suite 800, 1100 North Glebe Road, Arlington, VA 22201-4714 (US).
- (81) Designated States (*national*): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— with international search report
- (48) Date of publication of this corrected version:  
14 February 2002
- (15) Information about Corrections:  
see PCT Gazette No. 07/2002 of 14 February 2002, Section II  
Previous Correction:  
see PCT Gazette No. 35/2000 of 31 August 2000, Section II
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 00/43395 A1

(54) Title: SUBSTITUTED PORPHYRINS

(57) Abstract: The present invention relates, in general, to a method of modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and compositions suitable for use in such methods.

## SUBSTITUTED PORPHYRINS

### TECHNICAL FIELD

The present invention relates, in general, to a method of modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and compositions suitable for use in such methods.


### BACKGROUND

Oxidants are produced as part of the normal metabolism of all cells but also are an important component of the pathogenesis of many disease processes. Reactive oxygen species, for example, are critical elements of the pathogenesis of diseases of the lung, the cardiovascular system, the gastrointestinal system, the central nervous system and skeletal muscle. Oxygen free radicals also play a role in modulating the effects of nitric oxide (NO $\cdot$ ). In this context, they contribute to the pathogenesis of vascular disorders, inflammatory diseases and the aging process.

A critical balance of defensive enzymes against oxidants is required to maintain normal cell and organ function. Superoxide dismutases (SODs) are a family of metalloenzymes that catalyze the intra- and extracellular conversion of O $_2^{\cdot -}$  into H $_2$ O $_2$  plus O $_2$ , and represent the first line of defense against the detrimental effects of superoxide radicals. Mammals produce three distinct SODs. One is a dimeric copper- and zinc-containing enzyme (CuZn SOD) found in the cytosol of all cells. A second is a tetrameric manganese-containing SOD (Mn SOD) found within mitochondria, and the third is a tetrameric, glycosylated, copper- and

WHAT IS CLAIMED IS:


1. A compound of formula




or pharmaceutically acceptable salt thereof,


wherein

$R_1$  and  $R_3$  are the same and are:



$R_2$  and  $R_4$  are the same and are:







Y is halogen or  $-\text{CO}_2\text{X}$ , and

X is the same or different and is an alkyl and each  $\text{R}_5$  is the same or different and is H or alkyl.

wherein when  $\text{R}_1$  and  $\text{R}_2$  are -H,  $\text{R}_3$  and  $\text{R}_4$  are not



when  $\text{R}_1$  and  $\text{R}_2$  are -H, and  $\text{R}_3$  and  $\text{R}_4$  are





, said compound is

complexed with a metal selected from the group consisting of manganese, iron, copper, cobalt or nickel.

2. The compound according to claim 1 wherein  $\text{R}_1$  and  $\text{R}_2$  are the same and are:


-H,  $\text{CF}_3$ ,  $-\text{CO}_2\text{X}$ ,



or



$R_2$  and  $R_4$  are the same and are :




Y is -F or  $-\text{CO}_2\text{X}$ , and

X is the same or different and is a  $\text{C}_{1-4}$  alkyl and each  $R_5$  is the same or different and is H or  $\text{C}_{1-4}$  alkyl.

3. The compound according to claim 2 wherein X is methyl or ethyl.

4. The compound according to claim 1 wherein  $R_1$ ,  $R_2$ ,  $R_3$  and  $R_4$  are the same.

5. The compound according to claim 1 wherein  $R_1$ ,  $R_2$ ,  $R_3$  and  $R_4$  are



6. The compound according to claim 5 wherein X is methyl or ethyl.

7. The compound according to claim 5 wherein  $R_1$ ,  $R_2$ ,  $R_3$  and  $R_4$  are the same.


8. The compound according to claim 7 wherein  $R_1$ ,  $R_2$ ,  $R_3$  and  $R_4$  are



9. The compound according to claim 1 wherein said compound is complexed with a metal selected from the group consisting of zinc, iron, nickel, cobalt, copper, manganese.

10. The compound according to claim 9 wherein said compound is complexed with manganese.


11. A method of protecting cells from oxidant-induced toxicity comprising contacting said cells with a protective amount of a compound of formula




or pharmaceutically acceptable salt thereof,

wherein

$R_1$  and  $R_2$  are the same and are:




$R_3$  and  $R_4$  are the same and are :



Y is halogen or  $-CO_2X$ , and

X is the same or different and is an alkyl and each  $R_i$  is the same or different and is H or alkyl, so that said protection is effected.

12. The method according to claim 11 wherein said compound is complexed with a metal selected from the group consisting of manganese, iron, copper, cobalt, nickel or zinc.
13. The method according to claim 12 wherein said metal is manganese.
14. The method according to claim 11 wherein said cells are mammalian cells.
15. The method according to claim 14 wherein said cells are cells of an isolated organ.
16. The method according to claim 14 wherein said cells are cells of an organ transplant.
17. A method of treating a patient suffering from a condition that results from or that is exacerbated by oxidant-induced toxicity comprising administering to said patient an effective amount of a compound of formula







or pharmaceutically acceptable salt thereof,

wherein

$R_1$  and  $R_2$  are the same and are:



$R_3$  and  $R_4$  are the same and are:




Y is halogen or  $-\text{CO}_2\text{X}$ , and

X is the same or different and is an alkyl and each  $\text{R}_i$  is the same or different and is H or alkyl,  
so that said treatment is effected.

18. The method according to claim 17 wherein said compound is complexed with a metal selected from the group consisting of manganese, iron, copper, cobalt, nickel or zinc.


19. The method according to claim 18 wherein said compound is complexed with manganese.

20. A method of treating a pathological condition of a patient resulting from degradation of  $\text{NO}^+$  or a biologically active form thereof, comprising administering to said patient an effective amount of a compound of formula




or pharmaceutically acceptable salt thereof,  
wherein

$R_1$  and  $R_2$  are the same and are:



$R_2$  and  $R_3$  are the same and are :




$Y$  is halogen or  $-CO_2X$ , and

$X$  is the same or different and is an alkyl and each  $R_i$  is the same or different and is H or alkyl, so that said treatment is effected.

21. The method according to claim 20 wherein said compound is complexed with a metal selected from the group consisting of manganese, iron, copper, cobalt, nickel or zinc.

22. The method according to claim 21 wherein said compound is complexed with manganese.


23. A method of treating a patient for an inflammatory disease comprising administering to said patient an effective amount of a compound of formula




or pharmaceutically acceptable salt thereof.


wherein

$R_1$  and  $R_2$  are the same and are:





$R_2$  and  $R_4$  are the same and are :



Y is halogen or  $-\text{CO}_2\text{X}$ , and

X is the same or different and is an alkyl and each  $R_5$  is the same or different and is H or alkyl,  
so that said treatment is effected.

24. The method according to claim 23 wherein said compound is complexed with a metal selected from the group consisting of manganese, iron, copper, cobalt, nickel or zinc.

25. The method according to claim 24 wherein said compound is complexed with manganese.


26. The method according to claim 23 wherein said inflammatory disease is an inflammatory lung disease.

27. The method according to claim 26 wherein said inflammatory lung disease is bronchopulmonary disease.

28. The method according to claim 26 wherein said inflammatory lung disease is asthma.

29. The method according to claim 26 wherein said inflammatory lung disease is pulmonary fibrosis.

30. A method of treating a patient for an ischemic reperfusion injury comprising administering to said patient an effective amount of a compound of formula





I


or pharmaceutically acceptable salt thereof,

wherein

$R_1$  and  $R_3$  are the same and are:



$R_2$  and  $R_4$  are the same and are :



Y is halogen or  $-CO_2X$ , and

X is the same or different and is an alkyl and each  $R_5$  is the same or different and is H or alkyl, so that said treatment is effected.

31. The method according to claim 30 wherein said compound is complexed with a metal selected from the group consisting of manganese, iron, copper, cobalt, nickel or zinc.

32. The method according to claim 31 wherein said compound is complexed with manganese.

33. The method according to claim 30 wherein said ischemic reperfusion injury results from a stroke.